Lisata Therapeutics Inc. (LSTA)
| Bid | 2.15 |
| Market Cap | 18.62M |
| Revenue (ttm) | 1.01M |
| Net Income (ttm) | -20.14M |
| EPS (ttm) | -2.51 |
| PE Ratio (ttm) | -0.86 |
| Forward PE | -1.17 |
| Analyst | Buy |
| Ask | 2.77 |
| Volume | 26,748 |
| Avg. Volume (20D) | 45,086 |
| Open | 2.31 |
| Previous Close | 2.38 |
| Day's Range | 2.14 - 2.36 |
| 52-Week Range | 2.14 - 4.20 |
| Beta | 1.15 |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfun...
Analyst Forecast
According to 1 analyst ratings, the average rating for LSTA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 594.44% from the latest price.
4 days ago · proactiveinvestors.com
Lisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progressLisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a statement accompanying its full-year 2024 financial results. The pharmaceutical ...
1 month ago · proactiveinvestors.com
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMILisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compay's pancreatic cancer trials. The company recently announced preliminary results from its Phase 2ASCE...
1 month ago · proactiveinvestors.com
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trialLisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in com...
1 month ago · proactiveinvestors.com
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trialLisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is ...
2 months ago · proactiveinvestors.com
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnershipLisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead investigational drug candidate, certepetide. The company ...
2 months ago · proactiveinvestors.com
Lisata Therapeutics completes patient enrollment for CENDIFOX trialLisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX trial evaluating the safety and efficacy of Lisata's investiga...